Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3679277 | 0.83 | CA2 (0.39) | CA2NR1H4GABRA1GABRB2ALDH1A1 | |
| SCHEMBL3298793 | 0.81 | NLRP3 (0.36) | CA2GABRA1GABRB2ALDH1A1KDM4E | |
| SCHEMBL3096012 | 0.80 | CA2 (0.50) | CA2NR1H4GABRA1GABRB2ALDH1A1 | |
| SCHEMBL3298464 | 0.78 | ALDH1A1 (0.43) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL30921753 | 0.78 | CA2 (0.48) | CA2NR1H4GABRA1GABRB2ALDH1A1 | |
| SCHEMBL3296752 | 0.77 | ALDH1A1 (0.39) | CA2ALDH1A1KDM4ESMN1; SMN2NLRP3 | |
| SCHEMBL3298138 | 0.77 | CA2 (0.40) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL3299989 | 0.75 | ALDH1A1 (0.34) | CA2ALDH1A1TSHRKDM4EMAPK1 | |
| SCHEMBL3295228 | 0.75 | SMN1; SMN2 (0.45) | CA2ALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL6677826 | 0.72 | CA2 (0.43) | CA2NR1H4GABRA1GABRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741393-B2 | Organic silicon-based compound and method of producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | ARSA, OR10J3, HDAC10 | CA2 3413/4885NR1H4 3992/4885GABRA1 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.